Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments
Author:
Funder
Daiichi-Sankyo
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00432-021-03784-3.pdf
Reference28 articles.
1. Bardia A et al (2017) Efficacy and safety of anti-trop-2 antibody drug conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol 35:2141–2148. https://doi.org/10.1200/JCO.2016.70.8297
2. Bardia A et al (2019) Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 380:741–751. https://doi.org/10.1056/NEJMoa1814213
3. Bartley AN et al (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35:446–464. https://doi.org/10.1200/JCO.2016.69.4836
4. Boutsikou E, Domvri K, Hardavella G, Tsiouda D, Zarogoulidis K, Kontakiotis T (2018) Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice. Ther Adv Med Oncol 10:1758835918768238. https://doi.org/10.1177/1758835918768238
5. Cubas R, Li M, Chen C, Yao Q (2009) Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 1796:309–314. https://doi.org/10.1016/j.bbcan.2009.08.001
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back;Frontiers in Immunology;2024-08-15
2. Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors;Cell Reports Medicine;2024-08
3. Stem Cells/Lung Organoids and Lung Rejuvenation in the Treatment of Chronic Obstructive Pulmonary Disease and Pulmonary Emphysema;Comprehensive Hematology and Stem Cell Research;2024
4. The Impact of Trophoblast Cell-Surface Antigen 2 Expression on the Survival of Patients with Gastrointestinal Tumors: A Systematic Review;Journal of Personalized Medicine;2023-09-28
5. Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer;Clinical Cancer Research;2023-04-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3